Study Uncovers Two-Phase T-Cell Priming Process in Immune Response

Researchers from the University of Würzburg  have identified a two-phase process in T-cell priming, revealing how the immune system selectively activates and amplifies defense cells during viral infections. Their findings challenge previous assumptions about how T cells specialize and proliferate to optimize immune responses.

T-cell priming begins when rare T cells encounter dendritic cells (DCs) in lymph nodes. DCs present antigens—pathogen fragments—to T cells, initiating a 24-hour activation phase. During this time, T cells remain in contact with DCs, receiving signals that guide their specialization. Once activated, T cells detach, migrate, and proliferate rapidly. Some become effector cells to fight pathogens immediately, while others develop into memory cells for quicker responses to future infections. 

The study introduces a second phase of priming that refines the immune response further. "While the first phase of priming serves to activate a broad range of specific T cells, the newly identified second phase is responsible for selecting and specifically expanding those T cells that can recognize the pathogen most effectively. This ensures that the immune response is optimized for maximum efficiency," explains Katarzyna Jobin, first author on the paper published in Science.

In this second phase, T cells re-cluster with DCs in specific lymph node areas facilitated by CXCR3 expression on CD8 T cells. They receive IL-2 signals from CD4 helper T cells, which are essential for optimal proliferation. This cyclical activation process highlights how the immune system fine-tunes its response.

The findings have implications for immunotherapies targeting chronic infections and cancers, such as CAR-T cell treatments. "We hope that our new insights will help deepen our understanding of how to optimize T-cell-based therapies, and that they will shed light on why these treatments sometimes fail," says co-senior author Georg Gasteiger.